Payment overview · 2025
General Payments
$167.43
7 reported records · 7 companies
Healthcare provider profile · identity verified
Radu I Ciubuc, MD
Allopathic & Osteopathic Physicians|Internal Medicine|Geriatric Medicine · EL PASO, TX · NPI 1568477321
Verified facts
What the public records show
CMS Open Payments records show Radu I Ciubuc, MD received $167.43 in general payments during 2025 across 7 reported records.
Alpha Cognition USA, Inc. accounted for 27.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 6 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Gemtesa.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LOKELMA as an associated drug or biological on 6897 records involving 4326 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Lokelma by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 67 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Alpha Cognition USA, Inc. | Unresolved — no canonical attribution shown | $45.61 | 27.2% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $27.97 | 16.7% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $20.91 | 12.5% | 1 | 2025 |
| GE HEALTHCARE | Unresolved — no canonical attribution shown | $20.86 | 12.5% | 1 | 2025 |
| C2N Diagnostics, LLC | Unresolved — no canonical attribution shown | $18.75 | 11.2% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $16.93 | 10.1% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $16.40 | 9.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $167.43 | 7 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Zunveyl Normalized: zunveyl |
Drug | Alpha Cognition USA, Inc. | $45.61 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $27.97 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $20.91 | 1 | 2025 |
Source payment records
|
|||||
| PRECIVITYAD2 Normalized: precivityad2 |
Device | C2N Diagnostics, LLC | $18.75 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $16.93 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $16.40 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 26 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 67 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | LOKELMA open payments reported associated product |
CMS Open Payments — General Payments 6897 supporting records · 4326 recipient NPIs · example record 1206131624 |
Lokelma · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
67 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 1630 | 163 |
| Sertraline Hcl | Sertraline Hcl | 1458 | 160 |
| Lisinopril | Lisinopril | 967 | 109 |
| Atorvastatin Calcium | Atorvastatin Calcium | 903 | 111 |
| Metformin Hcl | Metformin Hcl | 823 | 74 |
| Tamsulosin Hcl | Tamsulosin Hcl | 774 | 90 |
| Donepezil Hcl | Donepezil Hcl | 679 | 81 |
| Trazodone Hcl | Trazodone Hcl | 658 | 84 |
| Gabapentin | Gabapentin | 628 | 70 |
| Amlodipine Besylate | Amlodipine Besylate | 548 | 71 |
| Escitalopram Oxalate | Escitalopram Oxalate | 482 | 51 |
| Memantine Hcl | Memantine Hcl | 401 | 51 |
| Divalproex Sodium | Divalproex Sodium | 394 | 43 |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 374 | 46 |
| Finasteride | Finasteride | 340 | 28 |
| Furosemide | Furosemide | 336 | 53 |
| Losartan Potassium | Losartan Potassium | 266 | 44 |
| Januvia | Sitagliptin Phosphate | 261 | 20 |
| Pantoprazole Sodium | Pantoprazole Sodium | 260 | 44 |
| Mirtazapine | Mirtazapine | 258 | 48 |
| Quetiapine Fumarate | Quetiapine Fumarate | 243 | 29 |
| Valproic Acid | Valproic Acid | 236 | 33 |
| Simvastatin | Simvastatin | 225 | 24 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 222 | 40 |
| Tramadol Hcl | Tramadol Hcl | 213 | 75 |
| Buspirone Hcl | Buspirone Hcl | 211 | 29 |
| Metoprolol Tartrate | Metoprolol Tartrate | 204 | 28 |
| Lactulose | Lactulose | 203 | 62 |
| Eliquis | Apixaban | 202 | 30 |
| Risperidone | Risperidone | 197 | 23 |
| Clopidogrel | Clopidogrel Bisulfate | 182 | 20 |
| Carvedilol | Carvedilol | 174 | 28 |
| Potassium Chloride | Potassium Chloride | 163 | 28 |
| Montelukast Sodium | Montelukast Sodium | 160 | 21 |
| Levetiracetam | Levetiracetam | 147 | 18 |
| Duloxetine Hcl | Duloxetine Hcl | 143 | 19 |
| Nifedipine Er | Nifedipine | 138 | 19 |
| Oxcarbazepine | Oxcarbazepine | 134 | 13 |
| Myrbetriq | Mirabegron | 131 | 19 |
| Paroxetine Hcl | Paroxetine Hcl | 131 | 12 |
| Xarelto | Rivaroxaban | 127 | 16 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 125 | 18 |
| Namzaric | Memantine Hcl/Donepezil Hcl | 123 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 118 | 22 |
| Pregabalin | Pregabalin | 115 | 21 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 107 | 17 |
| Olanzapine | Olanzapine | 105 | 13 |
| Citalopram Hbr | Citalopram Hydrobromide | 103 | 11 |
| Latanoprost | Latanoprost | 103 | 17 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 96 | 24 |
| Ibuprofen | Ibuprofen | 95 | 37 |
| Aripiprazole | Aripiprazole | 94 | 15 |
| Omeprazole | Omeprazole | 85 | 15 |
| Alendronate Sodium | Alendronate Sodium | 82 | 14 |
| Famotidine | Famotidine | 82 | 21 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 82 | 52 |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 76 | 16 |
| Enulose | Lactulose | 76 | 38 |
| Zolpidem Tartrate | Zolpidem Tartrate | 75 | 23 |
| Hydralazine Hcl | Hydralazine Hcl | 71 | 20 |
| Sodium Chloride | 0.9 % Sodium Chloride | 71 | 49 |
| Hydrochlorothiazide | Hydrochlorothiazide | 70 | 12 |
| Metoprolol Succinate | Metoprolol Succinate | 70 | 13 |
| Alprazolam | Alprazolam | 69 | 14 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 68 | 26 |
| Gemtesa | Vibegron | 67 | suppressed |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 67 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 67 | suppressed |
| Lorazepam | Lorazepam | 64 | 17 |
| Glipizide | Glipizide | 62 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 58 | suppressed |
| Spironolactone | Spironolactone | 58 | suppressed |
| Azithromycin | Azithromycin | 56 | 42 |
| Nystatin | Nystatin | 56 | 28 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 56 | 12 |
| Memantine Hcl Er | Memantine Hcl | 55 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 55 | 29 |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 55 | suppressed |
| Prednisone | Prednisone | 55 | 33 |
| Warfarin Sodium | Warfarin Sodium | 54 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 51 | 36 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 50 | suppressed |
| Jardiance | Empagliflozin | 50 | suppressed |
| Lacosamide | Lacosamide | 46 | suppressed |
| Levemir Flexpen | Insulin Detemir | 46 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 46 | 24 |
| Venlafaxine Hcl | Venlafaxine Hcl | 46 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 45 | suppressed |
| Rivastigmine | Rivastigmine | 45 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 44 | 14 |
| Lamotrigine | Lamotrigine | 44 | suppressed |
| Meloxicam | Meloxicam | 43 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 42 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 38 | suppressed |
| Clonazepam | Clonazepam | 38 | 15 |
| Linzess | Linaclotide | 37 | suppressed |
| Temazepam | Temazepam | 36 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 36 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 35 | suppressed |
| Levofloxacin | Levofloxacin | 32 | 27 |
| Santyl | Collagenase Clostridium Hist. | 32 | 12 |
| Brimonidine Tartrate-Timolol | Brimonidine Tartrate/Timolol | 31 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 31 | 22 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 31 | 26 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 31 | 11 |
| Metoclopramide Hcl | Metoclopramide Hcl | 31 | suppressed |
| Cephalexin | Cephalexin | 30 | 23 |
| Valsartan | Valsartan | 30 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 29 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 28 | 22 |
| Pentoxifylline | Pentoxifylline | 28 | suppressed |
| Lovastatin | Lovastatin | 27 | suppressed |
| Sucralfate | Sucralfate | 27 | suppressed |
| Allopurinol | Allopurinol | 26 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 26 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 26 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 26 | suppressed |
| Invega Sustenna | Paliperidone Palmitate | 26 | suppressed |
| Atenolol | Atenolol | 25 | suppressed |
| Baclofen | Baclofen | 25 | suppressed |
| Paliperidone Er | Paliperidone | 25 | suppressed |
| Vyzulta | Latanoprostene Bunod | 25 | suppressed |
| Carbamazepine | Carbamazepine | 24 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 24 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 24 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 24 | suppressed |
| Entacapone | Entacapone | 23 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 23 | suppressed |
| Methotrexate | Methotrexate Sodium | 23 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 23 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 23 | suppressed |
| Vancomycin Hcl | Vancomycin/Water For Inj (Peg) | 23 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 22 | 13 |
| Febuxostat | Febuxostat | 22 | suppressed |
| Glimepiride | Glimepiride | 22 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 22 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 21 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 21 | suppressed |
| Levemir | Insulin Detemir | 21 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 21 | suppressed |
| Xifaxan | Rifaximin | 21 | suppressed |
| Anastrozole | Anastrozole | 20 | suppressed |
| Fluconazole | Fluconazole | 20 | 14 |
| Timolol Maleate | Timolol Maleate | 20 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 19 | 17 |
| Doxazosin Mesylate | Doxazosin Mesylate | 19 | suppressed |
| Glucagen | Glucagon | 19 | 12 |
| Propranolol Hcl | Propranolol Hcl | 19 | suppressed |
| Erythromycin | Erythromycin Base | 18 | 12 |
| Topiramate | Topiramate | 18 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Budesonide | Budesonide | 17 | 12 |
| Ingrezza | Valbenazine Tosylate | 17 | suppressed |
| Amoxicillin | Amoxicillin | 16 | 14 |
| Celecoxib | Celecoxib | 16 | suppressed |
| Cyclosporine | Cyclosporine | 16 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 16 | suppressed |
| Ramelteon | Ramelteon | 16 | suppressed |
| Calcitriol | Calcitriol | 15 | suppressed |
| Glucagon Emergency Kit | Glucagon | 15 | 12 |
| Isoniazid | Isoniazid | 15 | suppressed |
| Misoprostol | Misoprostol | 15 | suppressed |
| Scopolamine | Scopolamine | 15 | suppressed |
| Dutasteride | Dutasteride | 14 | suppressed |
| Lidocaine Hcl | Lidocaine Hcl | 14 | 12 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 14 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 14 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 14 | suppressed |
| Calcium Acetate | Calcium Acetate | 13 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 13 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 13 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 13 | suppressed |
| Haloperidol Lactate | Haloperidol Lactate | 13 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 13 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 13 | suppressed |
| Sulindac | Sulindac | 13 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 12 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 12 | suppressed |
| Chlorthalidone | Chlorthalidone | 12 | suppressed |
| Clotrimazole | Clotrimazole | 12 | suppressed |
| Entresto | Sacubitril/Valsartan | 12 | suppressed |
| Estradiol | Estradiol | 12 | suppressed |
| Fentanyl | Fentanyl | 12 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 12 | suppressed |
| Ozempic | Semaglutide | 12 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 11 | 11 |
| Gemfibrozil | Gemfibrozil | 11 | suppressed |
| Haloperidol | Haloperidol | 11 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 11 | suppressed |
| Lokelma | Sodium Zirconium Cyclosilicate | 11 | suppressed |
| Lumigan | Bimatoprost | 11 | suppressed |
| Moxifloxacin | Moxifloxacin Hcl | 11 | suppressed |
| Nabumetone | Nabumetone | 11 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 11 | suppressed |
| Rytary | Carbidopa/Levodopa | 11 | suppressed |
| Tamoxifen Citrate | Tamoxifen Citrate | 11 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $167.43 · 7 records | Alpha Cognition USA, Inc. | Auvelity, FARXIGA, GEMTESA, Kerendia, PRECIVITYAD2, Zunveyl | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error